Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedJan 03, 2026
DataAggregated Company Financials
Companies58
  • 7D-0.2%
  • 3M-7.1%
  • 1Y7.0%
  • YTD0%

Over the last 7 days, the Pharma industry has remained flat, although notably Trulieve Cannabis gained 9.3%. As for the the longer term, the industry is up 7.0% over the past 12 months. Earnings are forecast to grow by 67% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 03 Jan 2026CA$16.1bCA$11.2b-CA$1,941,994,541.2216.6x-8.3x1.4x
Mon, 01 Dec 2025CA$13.6bCA$11.3b-CA$1,932,543,893.6614.7x-7x1.2x
Wed, 29 Oct 2025CA$16.5bCA$11.2b-CA$2,034,307,486.8332.2x-8.1x1.5x
Fri, 26 Sep 2025CA$16.5bCA$11.3b-CA$2,044,636,783.4937.1x-8.1x1.5x
Sun, 24 Aug 2025CA$17.0bCA$11.9b-CA$2,547,616,462.5837.4x-6.7x1.4x
Tue, 22 Jul 2025CA$10.5bCA$11.7b-CA$2,542,882,578.0119.6x-4.1x0.9x
Thu, 19 Jun 2025CA$9.7bCA$11.7b-CA$2,521,609,040.4018.6x-3.8x0.8x
Sat, 17 May 2025CA$9.3bCA$10.3b-CA$2,196,101,034.1917.5x-4.2x0.9x
Mon, 14 Apr 2025CA$9.0bCA$12.0b-CA$2,575,308,685.7818.3x-3.5x0.7x
Wed, 12 Mar 2025CA$10.7bCA$12.3b-CA$2,666,332,826.2821.8x-4x0.9x
Fri, 07 Feb 2025CA$13.1bCA$12.1b-CA$2,317,556,244.3320x-5.6x1.1x
Sun, 05 Jan 2025CA$13.6bCA$12.2b-CA$2,418,973,688.8729.2x-5.6x1.1x
Tue, 03 Dec 2024CA$14.3bCA$11.9b-CA$2,570,523,817.0621x-5.5x1.2x
Thu, 31 Oct 2024CA$19.0bCA$11.9b-CA$2,720,435,089.7818.2x-7x1.6x
Sat, 28 Sep 2024CA$18.3bCA$11.6b-CA$2,688,817,395.2727.7x-6.8x1.6x
Mon, 26 Aug 2024CA$18.4bCA$11.5b-CA$2,732,773,282.3122.9x-6.7x1.6x
Wed, 24 Jul 2024CA$20.9bCA$11.8b-CA$3,202,785,977.7319.4x-6.5x1.8x
Fri, 21 Jun 2024CA$19.3bCA$11.8b-CA$2,763,214,023.8413.2x-7x1.6x
Sun, 19 May 2024CA$25.0bCA$11.9b-CA$3,482,212,392.6113.8x-7.2x2.1x
Tue, 16 Apr 2024CA$23.6bCA$12.0b-CA$3,481,091,673.739x-6.8x2x
Thu, 14 Mar 2024CA$18.7bCA$11.8b-CA$3,488,377,381.937.3x-5.3x1.6x
Sat, 10 Feb 2024CA$23.2bCA$11.9b-CA$6,793,157,598.9812.1x-3.4x2x
Mon, 08 Jan 2024CA$19.9bCA$12.3b-CA$6,734,378,985.009.9x-3x1.6x
Wed, 06 Dec 2023CA$19.1bCA$12.4b-CA$6,779,680,212.008.8x-2.8x1.5x
Fri, 03 Nov 2023CA$15.2bCA$12.4b-CA$7,347,686,682.0011x-2.1x1.2x
Sun, 01 Oct 2023CA$20.0bCA$12.3b-CA$7,314,101,909.0013.9x-2.7x1.6x
Tue, 29 Aug 2023CA$13.8bCA$13.1b-CA$8,125,947,812.0014.7x-1.7x1.1x
Thu, 27 Jul 2023CA$14.4bCA$13.1b-CA$9,706,874,910.0012x-1.5x1.1x
Sat, 24 Jun 2023CA$14.8bCA$13.1b-CA$9,509,166,704.0013.7x-1.6x1.1x
Mon, 22 May 2023CA$15.1bCA$13.3b-CA$10,456,113,561.0010.4x-1.4x1.1x
Wed, 19 Apr 2023CA$15.3bCA$13.3b-CA$9,935,183,987.0010.6x-1.5x1.2x
Fri, 17 Mar 2023CA$18.4bCA$13.8b-CA$10,602,810,861.009.6x-1.7x1.3x
Sun, 12 Feb 2023CA$19.4bCA$13.5b-CA$10,281,877,065.0010x-1.9x1.4x
Tue, 10 Jan 2023CA$19.9bCA$13.5b-CA$10,098,710,386.0013.4x-2x1.5x
Price to Earnings Ratio

-2x


Total Market Cap: CA$19.9bTotal Earnings: -CA$10,098,710,386.00Total Revenue: CA$13.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -4.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 5.9% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market0.13%
Healthcare-0.095%
Pharma-0.21%
Pharma-0.21%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TRUL Trulieve CannabisCA$11.919.3%
+CA$171.0m		45.4%PS1.2x
NGEN NervGen PharmaCA$7.9310.4%
+CA$59.4m		149.4%PE-24.6x
VRNO Verano HoldingsCA$1.815.8%
+CA$36.3m		-5.7%PS0.6x
SKNY LIR Life SciencesCA$1.9518.9%
+CA$23.3m		n/aPE-131.7x
CWEB Charlotte's Web HoldingsCA$0.5620.4%
+CA$15.1m		250.0%PS1.3x

Latest News

NGEN
CA$7.93
NervGen Pharma
7D
10.4%
1Y
149.4%
CXXI
CA$0.54
C21 Investments
7D
20.0%
1Y
111.8%

C21 Investments Inc.'s (CSE:CXXI) 26% Share Price Surge Not Quite Adding Up

Jan 02
C21 Investments Inc.'s (CSE:CXXI) 26% Share Price Surge Not Quite Adding Up
VREO
CA$0.82
Vireo Growth
7D
-3.5%
1Y
2.5%
CURA
CA$3.58
Curaleaf Holdings
7D
-4.8%
1Y
55.0%
TSND
CA$1.05
TerrAscend
7D
-4.5%
1Y
7.1%
TRUL
CA$11.91
Trulieve Cannabis
7D
9.3%
1Y
45.4%
GRIN
CA$0.70
Grown Rogue International
7D
7.7%
1Y
-25.5%

Is Grown Rogue International (CSE:GRIN) Using Debt Sensibly?

Dec 25
Is Grown Rogue International (CSE:GRIN) Using Debt Sensibly?
WEED
CA$1.64
Canopy Growth
7D
-7.9%
1Y
-61.4%

WEED: Medical Expansion Will Drive Future Upside For Shares

Analysts have nudged their price target on Canopy Growth higher to reflect an improved fair value estimate, rising from approximately $3.30 to $3.76. This revision is supported by slightly stronger projected revenue growth, a notable uplift in expected profit margins, and a lower anticipated future price to earnings multiple.
CWEB
CA$0.56
Charlotte's Web Holdings
7D
20.4%
1Y
250.0%
GTII
CA$11.10
Green Thumb Industries
7D
-0.4%
1Y
-8.0%
CRON
CA$3.69
Cronos Group
7D
-1.9%
1Y
23.4%
MDP
CA$3.09
Medexus Pharmaceuticals
7D
11.6%
1Y
-9.6%

MDP: Share Repurchase Program Will Drive Stronger Future Shareholder Returns

Analysts have raised their price target for Medexus Pharmaceuticals to approximately $8.00 per share from about $6.00, citing expectations of stronger revenue growth, a substantial improvement in profit margins, and a lower projected future P/E multiple that enhances the stock's valuation appeal. What's in the News Medexus Pharmaceuticals Inc.
VRNO
CA$1.81
Verano Holdings
7D
5.8%
1Y
-5.7%

VRNO: Expanded Licenses And Retail Footprint Will Drive Stronger Market Position

Analysts have reduced their average price target on Verano Holdings from approximately 184.62 to about 56.93 per share. This reflects updated expectations for stronger revenue growth and improving profit margins, but at a more conservative future earnings multiple.
ACB
CA$5.94
Aurora Cannabis
7D
-5.3%
1Y
-12.6%
SKNY
CA$1.95
LIR Life Sciences
7D
18.9%
1Y
n/a
PLTH
CA$0.28
Planet 13 Holdings
7D
-11.3%
1Y
-51.8%